Mobile App

As a follow up to our prior discussions I Thought I would attach the just published Nature Biotechnology article on the sequencing by the US Department of Energy Joint Genome Institute of “Myceliophtora thermophila”, a strain from the genus and species Dyadic's wild type isolate C1 apparently came from.  
 
What Dyadic has accomplished both scientifically and through a serendipitous mutation over the past 15 years is remarkable.  We have a fully proven programmable and industrially scalable biofactory (Our C1 improved and molecularly engineered fungal strains and molecular tools for programming the C1 variants are commercially proven).  This advanced biology, coupled with a myriad of Intellectual Property Rights (Global Patents), coupled with the attached two scientific publications highlights the vast potential that lies within Dyadic's C1 Platform Technology. 

This independent scientific article in Nature (one of the most respected scientific journals worldwide), which one of the authors is actually a Novozymes key senior scientist,  along with a variety of other renowned scientific experts in this field, demonstrates the power of what we avail over here at Dyadic (see reference 27  in the attached nbt.1976 - “Development of a mature fungal technology and production platform for industrial enzymes based on a Myceliophthora thermophila isolate, previously known as Chrysosporium lucknowense C1”).   Please note that reference 27 is the attached (C1 Review Article).

We at Dyadic have spent greater than a decade developing a very robust, versatile and powerful production system to turn these genes, as well as genes from other genomes into enzymes and proteins at large industrial scale affordably.   Dyadic has developed not only a very strong IP position in regards to its evolved C1 microorganism, but also to many of the genes published in this article.  These genes and other molecular tools we have developed are being used by Dyadic and its collaborators (such as Abengoa Bioenergy and Codexis (Shell's biofuel partner) to reprogram C1 variants to produce enzymes for use in the manufacturing of biofuels, biochemicals, bioplastics, biopolymers, and other biobased products.  Additionally Dyadic has been selling enzymes from C1,  and our other technologies for use in a growing number of industrial enzyme markets.  As announced in 2009, we have received GRAS notification from the USDA for a C1 cellulase enzyme for the fruit juice industry, demonstrating not only the efficiency of C1, but also the safety of enzymes produced therefrom for this application.

As outlined in the attached C1 Review Article, we at Dyadic have over the past 15 years created and avail over a large number of improved C1 variants (strains), and a corresponding large tool box of powerful molecular tools for improving both future C1 strains and our proven industrial fermentation technology (we have produced C1 enzymes commercially in up to 150,000 liter fermenters, beginning as early as 1996).

We anticipate that these two very recent publications will further aid in both accelerating and enumerating the commercial opportunities for leveraging C1 in a variety of industries.

We are open to collaborations, joint ventures, licensing, and other forms of partnerships to exploit this data, as well as our own sequencing and annotation data, utilizing our previously filed worldwide issued and pending patents covering not only hundreds of genes from C1, but also the molecular tools for improving and programming our industrially proven C1 strains to create the products of interest for diverse Billion dollar markets.  In addition to the Non-Exclusive Abengoa Bioenergy and Codexis licenses we have already entered into, amongst a variety of other research projects we are working on we are also carrying out fully funded research and development projects for Sanofi Pasteur and also one of the world's largest animal feed nutrition companies in order to create C1 strains to produce new vaccines and animal feed enzymes.

If you need to reach me in the mean time my cell is 561 889 8901

Have a great weekend

Mark

P.S. I’m not sure you have seen the recent news on Abengoa, who as you may recall along with Codexis is one of our non exclusive licensees of our C1 Platform Technology.  See summary information on Abengoa’s Press Releases below:

Abengoa welcomes leading energy private investment firm First Reserve Corporation as a new strategic shareholder

First Reserve Corporation will invest €300 million in Abengoa’s Class B shares in a deal that endorses the company’s plans and management. First Reserve will be a strategic partner that will also strengthen Abengoa’s financial capacity.

http://www.abengoa.com/corp/web/en/noticias_y_publicaciones/noticias/historico/2011/10_octubre/abg_20111004.html

Abengoa completes $132.4 million loan guarantee financing for its first biomass ethanol plant in Hugoton, Kansas

http://www.abengoa.com/corp/web/en/noticias_y_publicaciones/noticias/historico/2011/09_septiembre/abg_20110929_3.html

BNTEU starts the pre-production of enzymes on an industrial scale

http://www.abengoabioenergy.com/corp/web/en/prensa/noticias/historico/2011/bio_20110223_5.html

Enzymes for cellulose degradation

http://www.abengoabioenergy.com/corp/web/en/nuevas_tecnologias/tecnologias/enzimas/index.html